Publication: Target blood pressure and control status in Asia
dc.contributor.author | Yook Chin Chia | en_US |
dc.contributor.author | Kazuomi Kario | en_US |
dc.contributor.author | Yuda Turana | en_US |
dc.contributor.author | Jennifer Nailes | en_US |
dc.contributor.author | Jam Chin Tay | en_US |
dc.contributor.author | Saulat Siddique | en_US |
dc.contributor.author | Sungha Park | en_US |
dc.contributor.author | Jinho Shin | en_US |
dc.contributor.author | Peera Buranakitjaroen | en_US |
dc.contributor.author | Chen Huan Chen | en_US |
dc.contributor.author | Romeo Divinagracia | en_US |
dc.contributor.author | Satoshi Hoshide | en_US |
dc.contributor.author | Huynh Van Minh | en_US |
dc.contributor.author | Jorge Sison | en_US |
dc.contributor.author | Arieska Ann Soenarta | en_US |
dc.contributor.author | Guru Prasad Sogunuru | en_US |
dc.contributor.author | Apichard Sukonthasarn | en_US |
dc.contributor.author | Boon Wee Teo | en_US |
dc.contributor.author | Narsingh Verma | en_US |
dc.contributor.author | Yuqing Zhang | en_US |
dc.contributor.author | Tzung Dau Wang | en_US |
dc.contributor.author | Ji Guang Wang | en_US |
dc.contributor.other | University Medicine and Pharmacy, Hue University | en_US |
dc.contributor.other | De La Salle Health Sciences Institute | en_US |
dc.contributor.other | Sunway University | en_US |
dc.contributor.other | Hanyang University Medical Center | en_US |
dc.contributor.other | Jichi Medical University | en_US |
dc.contributor.other | Yonsei University Health System | en_US |
dc.contributor.other | Shanghai Jiao Tong University School of Medicine | en_US |
dc.contributor.other | Madras Institute of Orthopaedics and Traumatology Hospitals | en_US |
dc.contributor.other | National Taiwan University Hospital | en_US |
dc.contributor.other | Kathmandu University | en_US |
dc.contributor.other | University of the East Ramon Magsaysay Memorial Medical Center | en_US |
dc.contributor.other | Fatima Memorial Hospital | en_US |
dc.contributor.other | National Yang-Ming University Taiwan | en_US |
dc.contributor.other | Universitas Katolik Indonesia Atma Jaya | en_US |
dc.contributor.other | Universitas Indonesia | en_US |
dc.contributor.other | University of Malaya | en_US |
dc.contributor.other | Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College | en_US |
dc.contributor.other | Yong Loo Lin School of Medicine | en_US |
dc.contributor.other | King George's Medical University | en_US |
dc.contributor.other | Faculty of Medicine, Siriraj Hospital, Mahidol University | en_US |
dc.contributor.other | Tan Tock Seng Hospital | en_US |
dc.contributor.other | Bangkok Hospital Chiang Mai | en_US |
dc.date.accessioned | 2020-05-05T05:42:19Z | |
dc.date.available | 2020-05-05T05:42:19Z | |
dc.date.issued | 2020-03-01 | en_US |
dc.description.abstract | © 2019 Wiley Periodicals, Inc. It is widely accepted that hypertension constitutes a significant cardiovascular risk factor and that treating high blood pressure (BP) effectively reduces cardiovascular risk. An important issue in Asia is not just the high prevalence of hypertension, particularly in some countries, but also the low level of awareness and treatment rates in many regions. The 2017 update of the American College of Cardiology/American Heart Association hypertension guidelines raised the question about which BP threshold should be used to diagnose and treat hypertension. Although there is a theoretical rationale for a stricter BP criterion in Asia given the ethnic-specific features of hypertension in the region, the majority of countries in Asia have retained a diagnostic BP threshold of ≥140/90 mm Hg. Although lowering thresholds might make theoretical sense, this would increase the prevalence of hypertension and also markedly reduce BP control rates. In addition, there are currently no data from robust randomized clinical trials of the benefits of the lower targets in preventing cardiovascular disease and reducing cardiovascular risk, particularly in high-risk patients and especially for Asian populations. There is also no defined home BP treatment target level for an office BP treatment target of 130/80 mm Hg. However, in this regard, in the interim, lifestyle modifications, including reducing body weight and salt intake, should form an important part of hypertension management strategies in Asia, while studies on treating at lower BP threshold level in Asians and getting to lower BP targets will be helpful to inform and optimize the management of hypertension in the region. | en_US |
dc.identifier.citation | Journal of Clinical Hypertension. Vol.22, No.3 (2020), 344-350 | en_US |
dc.identifier.doi | 10.1111/jch.13714 | en_US |
dc.identifier.issn | 17517176 | en_US |
dc.identifier.issn | 15246175 | en_US |
dc.identifier.other | 2-s2.0-85075450586 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/54630 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075450586&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Target blood pressure and control status in Asia | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85075450586&origin=inward | en_US |